{"id":"NCT01529203","sponsor":"Galderma R&D","briefTitle":"Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range","officialTitle":"Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2013-04","completion":"2013-04","firstPosted":"2012-02-08","resultsPosted":"2014-04-25","lastUpdate":"2021-02-18"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Aging"],"interventions":[{"type":"DRUG","name":"Botulinum Toxin Type A (Azzalure)","otherNames":[]},{"type":"DEVICE","name":"Restylane ranges","otherNames":[]}],"arms":[{"label":"Azzalure and Restylane","type":"OTHER"}],"summary":"The aim of this study is to assess subjects' satisfaction linked to the pan facial management of rejuvenation with injections of Azzalure® and Restylane® fillers.\n\nThis will be an open, multi-centre study.","primaryOutcome":{"measure":"Subject Satisfaction for the Full Face","timeFrame":"Month 6","effectByArm":[{"arm":"Azzalure and Restylane","deltaMin":92.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":5,"countries":["France","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":60},"commonTop":["Skin swelling","Nasopharyngitis","Injection site haematoma","contusion","headache"]}}